SCHEMBL5220692

SCHEMBL5220692

O=C(O)C1=NCNc2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 1/20 0.53
GAA P10253 2/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HSD17B10 Q99714 2/20 0.38
HPGD P15428 1/20 0.38
MAPK1 P28482 1/20 0.38
NOTUM Q6P988 1/20 0.38
MAPT P10636 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35
GABRB2 P47870 1/20 0.35
PDPK1 O15530 1/20 0.34
PARP1 P09874 1/20 0.34
PARP10 Q53GL7 1/20 0.34
PARP11 Q9NR21 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylamine SCHEMBL27663588 0.95 NOS2 (0.53) NOS2GAAKDM4EALDH1A1HSD17B10
SCHEMBL28318614 0.80 NOS2 (0.47) NOS2GAAKDM4EALDH1A1HSD17B10
SCHEMBL5262502 0.76 NAPRT (0.40) KDM4EALDH1A1MAPTLMNANAPRT
SCHEMBL15650452 0.73 NOS2 (0.60) NOS2GABRA1GABRG2GABRB3GABRA5
SCHEMBL13585229 0.70 NOS2 (0.56) NOS2GAAALDH1A1MAPTGABRA1
SCHEMBL7940885 0.69 NOS2 (1.00) NOS2TSHR
SCHEMBL27416904 0.69 NOS2 (0.55) NOS2KDM4EALDH1A1HSD17B10HPGD
SCHEMBL27479358 0.69 NOS3 (0.52) NOS2KDM4EALDH1A1HPGDNOTUM
SCHEMBL37948 0.69 NISCH (0.32) KDM4E
Hydrochloric Acid SCHEMBL8382199 0.68 NOS2 (0.96) NOS2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023208173-A1 SUBSTITUTED 6- (PYRIMIDIN-4-YL) QUINOLINE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS BEIGENE , LTD. (KY) 2023-11-02 WO disclosed
WO-2021026672-A1 HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS NOVARTIS AG (CH) 2021-02-18 WO disclosed
CN-109641886-A bicyclic BET bromodomain inhibitors and uses thereof 康威基内有限公司 2019-04-16 CN disclosed
CN-1922171-B Pyrimidine derivative ASKA PHARM CO LTD 2012-10-17 CN disclosed
CN-1681811-B Azolidinone-vinyl fused-benzene derivatives APPLIED RESEARCH SYSTEMS 2010-05-26 CN disclosed
CN-101351453-A Heterocyclic amide compound and use thereof TAKEDA PHARMACEUTICAL (JP) 2009-01-21 CN disclosed
CN-101163683-A 4-0x0quinaz0lin-3-yl benzamide derivatives for the treatment of cytokine diseases ASTRAZENECA AB ASTRAZENECA UK (SE) 2008-04-16 CN disclosed
EP-1814552-A2 COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS Astex Therapeutics Limited (GB) 2007-08-08 EP disclosed
CN-1976907-A Heterocyclic amide compound and use thereof as an MMP-13 inhibitor TAKEDA PHARMACEUTICAL (JP) 2007-06-06 CN disclosed
EP-1740551-A1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR Takeda Pharmaceutical Company Limited (JP) 2007-01-10 EP disclosed
WO-2006051290-A2 COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS ASTEX THERAPEUTICS LIMITED (GB) 2006-05-18 WO disclosed
WO-2005105760-A1 HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-11-10 WO disclosed
CN-1681811-A Azolidinone-vinyl fused-benzene derivatives APPLIED RESEARCH SYSTEMS (AN) 2005-10-12 CN disclosed